Analex's Advanced Biosystems Subsidiary Awarded $2 Million Biodefense Contract by DARPA
Thursday May 1, 8:19 am ET
ALEXANDRIA, Va., May 1 /PRNewswire-FirstCall/ -- Analex Corporation (Amex: NLX - News) has announced that its Advanced Biosystems, Inc. subsidiary has been awarded approximately $2 million in additional funding by the Defense Advanced Research Projects Agency (DARPA). This ten-month contract builds upon medical biodefense research previously funded by DARPA, and initiates the development of additional capabilities and techniques for use in creating and evaluating surrogate lung tissues and their suitability as tools in the study of infection. Other members of Advanced Biosystems' team include George Mason University, Sciperio, Inc., and Structural Bioinformatics, Inc.
The research is being conducted under the direction of Advanced Biosystems' Vice Chairman and Chief Scientist, Dr. Ken Alibek. An expert in the development of these and other novel methods of prophylaxis (prevention) and treatment of infectious diseases, Dr. Alibek has focused on researching ways to enhance the body's innate immune response against a wide variety of biological weapons threats. The areas under investigation will include an expansion of prior in vitro and in vivo studies of the effects of certain cytokines and other modulators of the innate immune response; and further study of various tissue deposition techniques used in creating three- dimensional models of mucosal immunity.
"Our research continues to yield promising results, and we are pleased that DARPA has awarded us additional funding to develop advanced protection against biological threat agents," said Dr. Alibek. "Under this contract we will continue the development and small animal in vivo testing of prototype biodefense products. At the appropriate time, our Company intends to explore potential opportunities to license its developing technology to, or seek a joint venture with, a partner to complete the necessary clinical trials, regulatory approvals, and the development, manufacturing, and marketing of any future products that might arise from this work," he added.
Analex's President and Chief Executive Officer, Sterling Phillips, stated, "We are pleased that DARPA has awarded Advanced Biosystems this next-stage funding to continue to develop novel medical methods of protection against biological agents that may be used in warfare or terrorist attacks. This bio- defense research is another part of Analex's commitment to supporting national security."
Analex specializes in providing intelligence, systems engineering and biodefense services in support of our nation's security. Analex focuses on developing innovative technical approaches for the intelligence community, analyzing and supporting defense systems, designing, developing and testing aerospace systems and developing medical defenses and treatments for infectious agents used in biological warfare and terrorism. The company's stock trades on the American Stock Exchange under the symbol NLX. The company can be found on the Internet at www.analex.com. Analex investor relations can be contacted at (703) 329-9400 or via email at amber.gordon@analex.com.
PLEASE NOTE: Except for the historical information contained herein, this press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. These forward-looking statements may be identified by reference to a future period by use of forward-looking terminology such as "anticipate," "expect," "could," "intend," "may" and other words of a similar nature. There are certain important factors and risks that could cause results to differ materially from those anticipated by the statements contained herein. Such factors and risks include business conditions and growth in the medical research, pharmaceutical and government contracting arenas and in the economy in general. Competitive factors include the pressures toward consolidation of small government contracts into larger contracts awarded to major, multi-national corporations; and the Company's ability to continue to recruit and retain highly skilled scientific, technical, managerial and sales/marketing personnel. Other risks may be detailed from time to time in the Company's filings with the Securities and Exchange Commission. Analex undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
--------------------------------------------------------------------------------
Source: Analex Corporation
Copyright © 2003 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Ad Feedback
Copyright © 2003 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
